Armata制药公司近日宣布,已从美国国防部获得一笔总额250万美元的额外非稀释性奖励资金。这笔资金将专项用于支持其研发项目AP-Sa02的持续开发工作。此次拨款进一步巩固了公司与国防部门的合作关系,并为关键治疗方案的推进提供了重要的非股权融资支持。
Armata制药公司近日宣布,已从美国国防部获得一笔总额250万美元的额外非稀释性奖励资金。这笔资金将专项用于支持其研发项目AP-Sa02的持续开发工作。此次拨款进一步巩固了公司与国防部门的合作关系,并为关键治疗方案的推进提供了重要的非股权融资支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.